{
    "id": "dbpedia_2351_3",
    "rank": 64,
    "data": {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004845-18/DK",
        "read_more_link": "",
        "language": "en",
        "title": "Clinical Trials Register",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://www.clinicaltrialsregister.eu/ctr-search/img/euFlag.png",
            "https://www.clinicaltrialsregister.eu/ctr-search/img/printer.png",
            "https://www.clinicaltrialsregister.eu/ctr-search/img/ema_logo.png",
            "https://www.clinicaltrialsregister.eu/ctr-search/img/hma_logo.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "D.IMP: 1 D.1.2 and D.1.3IMP RoleTest D.2 Status of the IMP to be used in the clinical trial D.2.1IMP to be used in the trial has a marketing authorisation Yes D.2.1.1.1Trade name Avastin D.2.1.1.2Name of the Marketing Authorisation holderRoche Registration GmbH D.2.1.2Country which granted the Marketing AuthorisationEuropean Union D.2.5The IMP has been designated in this indication as an orphan drug in the Community No D.2.5.1Orphan drug designation number D.3 Description of the IMP D.3.4Pharmaceutical form Solution for infusion D.3.4.1Specific paediatric formulation No D.3.7Routes of administration for this IMPIntravenous use\n\nD.3.8 to D.3.10 IMP Identification Details (Active Substances) D.3.8INN - Proposed INNBEVACIZUMAB D.3.9.1CAS number 216974-75-3 D.3.9.4EV Substance CodeSUB16402MIG D.3.10 Strength D.3.10.1Concentration unit mg/ml milligram(s)/millilitre D.3.10.2Concentration typeequal D.3.10.3Concentration number25 D.3.11 The IMP contains an: D.3.11.1Active substance of chemical origin No D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes The IMP is a: D.3.11.3Advanced Therapy IMP (ATIMP) No D.3.11.3.1Somatic cell therapy medicinal product No D.3.11.3.2Gene therapy medical product No D.3.11.3.3Tissue Engineered Product No D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No D.3.11.5Radiopharmaceutical medicinal product No D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No D.3.11.7Plasma derived medicinal product No D.3.11.8Extractive medicinal product No D.3.11.9Recombinant medicinal product Yes D.3.11.10Medicinal product containing genetically modified organisms No D.3.11.11Herbal medicinal product No D.3.11.12Homeopathic medicinal product No D.3.11.13Another type of medicinal product No D.IMP: 2 D.1.2 and D.1.3IMP RoleComparator D.2 Status of the IMP to be used in the clinical trial D.2.1IMP to be used in the trial has a marketing authorisation Yes D.2.1.1.1Trade name Lonsurf D.2.1.1.2Name of the Marketing Authorisation holderLes Laboratoires Servier D.2.1.2Country which granted the Marketing AuthorisationEuropean Union D.2.5The IMP has been designated in this indication as an orphan drug in the Community No D.2.5.1Orphan drug designation number D.3 Description of the IMP D.3.4Pharmaceutical form Film-coated tablet D.3.4.1Specific paediatric formulation No D.3.7Routes of administration for this IMPOral use\n\nD.3.8 to D.3.10 IMP Identification Details (Active Substances) D.3.8INN - Proposed INNLonsurf D.3.9.1CAS number 733030-01-8 D.3.9.3Other descriptive nameTIPIRACIL HYDROCHLORIDE MIXTURE WITH TRIFLURIDINE D.3.9.4EV Substance CodeSUB78359 D.3.10 Strength D.3.10.1Concentration unit mg milligram(s) D.3.10.2Concentration typerange D.3.10.3Concentration number15 to 20 D.3.11 The IMP contains an: D.3.11.1Active substance of chemical origin No D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes The IMP is a: D.3.11.3Advanced Therapy IMP (ATIMP) No D.3.11.3.1Somatic cell therapy medicinal product No D.3.11.3.2Gene therapy medical product No D.3.11.3.3Tissue Engineered Product No D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No D.3.11.5Radiopharmaceutical medicinal product No D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No D.3.11.7Plasma derived medicinal product No D.3.11.8Extractive medicinal product No D.3.11.9Recombinant medicinal product No D.3.11.10Medicinal product containing genetically modified organisms No D.3.11.11Herbal medicinal product No D.3.11.12Homeopathic medicinal product No D.3.11.13Another type of medicinal product No E.1 Medical condition or disease under investigation E.1.1Medical condition(s) being investigated\n\nTRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in patients with platinum-refractory esophago-gastric adenocarcinoma Et randomiseret fase III studie med TRIFLURIDINE/TIPIRACIL (FTD/TPI) med eller uden bevacizumab til patienter med platin-resistent Øsofago-gastrisk adenocarcinom (LON-GAS).\n\nE.1.1.1Medical condition in easily understood language\n\nRandomised trial in patients with advanced cancer in esophagus and stomach with Lonsurf with or without bevacizumab Lodtrækningsforsøg til patienter med udbredt kræft i spiserør, mavemund og mavesæk med Lonsurf med eller uden bevacizumab\n\nE.1.1.2Therapeutic area Diseases [C] - Cancer [C04] MedDRA Classification E.1.3Condition being studied is a rare disease No E.2 Objective of the trial E.2.1Main objective of the trial\n\nThe purpose of this study is to evaluate the efficacy and tolerability of Lonsurf with or without bevacizumab in Caucasian patients with platinum-refractory esophago-gastric adenocarcinoma. Primary objective is Progression Free Survival (PFS) Formålet med studiet er at evaluere effekt og sikkerhed af Lonsurf med eller uden bevacizumab til kaukasiske patienter med platin-behandlet kræft i spiseør, mavemund og mavesæk. Det primære endemål er Progressionsfri Overlevelse (PFS)\n\nE.2.2Secondary objectives of the trial\n\nSecondary objectives include Overall survival (OS), Response rate (RR), Disease Control Rate, Time to Deterioration (TtD) in Performance Status, Toxicity and Correlation between bio-markers and outcome\n\nSekundære endemål omfatter overlevelse (OS), responsrate (RR), disease control rate (DCR), tid til forværring i Performance Status (PS), bivirkninger og relation mellem biomarkører og effektmål.\n\nE.2.3Trial contains a sub-study No E.5 End points E.5.1Primary end point(s)\n\nProgression Free Survival (PFS) Progressionsfri Overlevelse (PFS)\n\nE.5.1.1Timepoint(s) of evaluation of this end point\n\n6 months after end of trial (last visit last patient) 6 måneder efter forsøgets afslutning (last visit last patient)\n\nE.5.2Secondary end point(s)\n\nSecondary objectives include Overall survival (OS), Response rate (RR), Disease Control Rate (DCR), Time to deterioration (TtD) in Performance Status (PS), Toxicity and Correlation between bio-markers and outcome Sekundære endemål omfatter overlevelse (OS), responsrate (RR), disease control rate (DCR), tid til forværring i performance status, bivirkninger og relation mellem biomarkører og effektmål.\n\nE.5.2.1Timepoint(s) of evaluation of this end point\n\n6 months after end of trial (last visit last patient) 6 måneder efter forsøgets afslutning (last visit last patient)\n\nE.6 and E.7 Scope of the trial E.6Scope of the trial E.6.1Diagnosis No E.6.2Prophylaxis No E.6.3Therapy Yes E.6.4Safety Yes E.6.5Efficacy Yes E.6.6Pharmacokinetic No E.6.7Pharmacodynamic No E.6.8Bioequivalence No E.6.9Dose response No E.6.10Pharmacogenetic No E.6.11Pharmacogenomic No E.6.12Pharmacoeconomic No E.6.13Others No E.7Trial type and phase E.7.1Human pharmacology (Phase I) No E.7.1.1First administration to humans No E.7.1.2Bioequivalence study No E.7.1.3Other No E.7.1.3.1Other trial type description E.7.2Therapeutic exploratory (Phase II) No E.7.3Therapeutic confirmatory (Phase III) Yes E.7.4Therapeutic use (Phase IV) No E.8 Design of the trial E.8.1Controlled Yes E.8.1.1Randomised Yes E.8.1.2Open Yes E.8.1.3Single blind No E.8.1.4Double blind No E.8.1.5Parallel group No E.8.1.6Cross over No E.8.1.7Other No E.8.3 The trial involves single site in the Member State concerned No E.8.4 The trial involves multiple sites in the Member State concerned Yes E.8.4.1Number of sites anticipated in Member State concerned4 E.8.5The trial involves multiple Member States No E.8.6 Trial involving sites outside the EEA E.8.6.1Trial being conducted both within and outside the EEA No E.8.6.2Trial being conducted completely outside of the EEA No E.8.7Trial has a data monitoring committee No E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial\n\nLVLS Sidste patient sidste besøg\n\nE.8.9 Initial estimate of the duration of the trial E.8.9.1In the Member State concerned years2 E.8.9.1In the Member State concerned months6 E.8.9.1In the Member State concerned days"
    }
}